{
    "Trade/Device Name(s)": [
        "Wako Direct Bilirubin V"
    ],
    "Submitter Information": "Wako Chemicals, USA Inc.",
    "510(k) Number": "K053132",
    "Predicate Device Reference 510(k) Number(s)": [
        "K970986"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFM"
    ],
    "Summary Letter Date": "November 7, 2005",
    "Summary Letter Received Date": "November 9, 2005",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Direct bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Chemical oxidation (vanadate method)"
    ],
    "Methodologies": [
        "Photometric measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Wako Direct Bilirubin V, an assay for direct bilirubin determination in serum and plasma using vanadate oxidation chemistry",
    "Indications for Use Summary": "For determination of serum and plasma bilirubin to aid in the screening of liver function disorders or diagnosis of jaundice",
    "fda_folder": "Clinical Chemistry"
}